Venaxis to Present at Biotech Showcase™ 2014
Venaxis CEO Steve Lundy to Speak on Molecular Diagnostics Panel
CASTLE ROCK, Colo., Jan. 9, 2014
CASTLE ROCK, Colo., Jan. 9, 2014 /PRNewswire/ --Venaxis, Inc. (Nasdaq: APPY),
an in vitro diagnostic company focused on obtaining FDA clearance and
commercializing its CE Marked APPY1™ Test, a rapid, multiple biomarker-based
assay for identifying patients that are at low risk for appendicitis, today
announced it will present at the Biotech Showcase 2014 conference, to be held
January 13-15, 2014, at The Parc 55 Wyndham Hotel in San Francisco, CA.
Steve Lundy, President and CEO of Venaxis™, will provide an overview of the
Company's business during his live presentation and will be available to
participate in one-on-one meetings with investors who are registered to attend
Event: Biotech Showcase 2014
Date: Monday, January 13, 2014
Time: 2:00 pm (Pacific Time)
Location: Parc 55 Wyndham San Francisco Union Square Hotel
The presentation will be webcast live. To access the webcast, please visit
the investor relations section of the Venaxis website at
http://ir.venaxis.com. The webcast will be archived and available for 90 days.
Steve Lundy will also speak on a panel entitled "Molecular Diagnostics: Poised
to improve patient outcomes" at 8 a.m. on Monday, January 13, 2014 as part of
the Biotech Showcase conference. The panel sheds light on the next generation
of diagnostic tests and the paradigm shift towards personalized medicine.
Co-produced by Demy-Colton Life Science Advisors and EBD Group, Biotech
Showcase is an investor and partnering conference devoted to providing private
and public biotechnology and life sciences companies an opportunity to present
to, and meet with, investors and pharmaceutical executives during the course
of one of the industry's largest annual healthcare investor conferences. Now
in its sixth year, Biotech Showcase is expected to attract upwards of 1,500
About Venaxis, Inc.
Venaxis, Inc. is an in vitro diagnostic company focused on the clinical
development and commercialization of its CE Marked APPY1 Test, the Company's
rapid, protein biomarker-based assay for appendicitis. This unique
appendicitis test has projected high sensitivity and negative predictive value
and is being developed to aid in the identification of patients at low risk
for acute appendicitis, allowing for more conservative patient management.
The APPY1 Test is being developed initially for pediatric, adolescent and
young adult patients with abdominal pain, as this population is at the highest
risk for appendicitis and has the highest risk of long-term health effects
associated with CT imaging. While FDA clearance is being sought, an initial
launch for the APPY1 Test is ongoing in select European countries. For more
information, visit www.venaxis.com.
This press release includes "forward-looking statements" of Venaxis, Inc.
("Venaxis") as defined by the Securities and Exchange Commission ("SEC"). All
statements, other than statements of historical fact, included in this press
release that address activities, events or developments that Venaxis believes
or anticipates will or may occur in the future are forward-looking statements.
These statements are based on certain assumptions made based on experience,
expected future developments and other factors Venaxis believes are
appropriate in the circumstances. Such statements are subject to a number of
assumptions, risks and uncertainties, many of which are beyond the control of
Venaxis. Investors are cautioned that any such statements are not guarantees
of future performance. Actual results or developments may differ materially
from those projected in the forward-looking statements as a result of many
factors, including our ability to successfully complete required product
development and modifications in a timely and cost effective manner, complete
clinical trial activities for the APPY1 Test required for FDA submission,
obtain FDA clearance or approval, maintain CE Marking, cost effectively
manufacture and generate revenues from the APPY1 Test at a profitable price
point, execute agreements required to successfully advance the company's
objectives, retain the management team to advance the products, overcome
adverse changes in market conditions and the regulatory environment, obtain
and enforce intellectual property rights, and realize value of intangible
assets. Furthermore, Venaxis does not intend (and is not obligated) to update
publicly any forward-looking statements. The contents of this press release
should be considered in conjunction with the risk factors contained in
Venaxis' recent filings with the SEC, including its Form 10-Q for the quarter
ended June 30, 2013.
Venaxis and APPY1 are trademarks of Venaxis, Inc.
For Investors and Media:
Tiberend Strategic Advisors, Inc.
Joshua Drumm, PhD
firstname.lastname@example.org; (212) 375-2664
email@example.com; (212) 375-2686
SOURCE Venaxis, Inc.
Press spacebar to pause and continue. Press esc to stop.